Author

J. Koster

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 10 Animal Behavior & Cognition· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 10 Approach:experimental assay· 9 Assay:bulk RNA-seq· 7 Approach:statistical model· 7 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3

Frequent Co-Authors

R. Versteeg· 4 shared B. Koopmans· 2 shared D. A. Zwijnenburg· 2 shared E. M. Westerhout· 2 shared H. N. Caron· 2 shared J. J. Molenaar· 2 shared J. van Nes· 2 shared L. Schild· 2 shared

Activity by Year

2018-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. Versteeg

Mutual co-authors in cluster

Author profile →

13 papers

Recent·Most cited

Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors

D. S. Metselaar, M. H. Meel, J. R. Goulding, P. Waranecki, M. C. de Gooijer, M. Breur, J. Koster, S. E. Veldhuijzen van Zanten, M. Bugiani, P. Wesseling, G. J. Kaspers, E. Hulleman

This study shows gemcitabine selectively kills ATRT by degrading SIRT1, activating p53 and SHH signaling, and significantly improves survival in xenograft models.

bioRxiv · Sep 2, 2023Cancer Biology

Two opposing gene expression patterns within ATRX aberrant neuroblastoma

M. R. van Gerven, L. Schild, J. van Arkel, B. Koopmans, L. A. Broeils, L. A. M. Meijs, R. van Oosterhout, M. M. van Noesel, J. Koster, S. R. van Hooff, J. J. Molenaar, M. van den Boogaard

The paper identifies two opposing gene expression patterns in ATRX-aberrant neuroblastoma models, suggesting distinct molecular mechanisms and treatment implications.

bioRxiv · Oct 25, 2022 · PreprintCancer Biology

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

J. Wienke, L. L. Visser, W. M. Kholosy, K. M. Keller, M. Barisa, S. Munnings-Tomes, E. Carlton, E. Poon, A. Rodriguez, R. Bernardi, F. Van den Ham, S. R. Van Hooff, Y. A. H. Matser, M. Tas, K. P. S. Langenberg, , J. J Molenaar

The paper uses single-cell RNA sequencing to analyze neuroblastoma and identifies the NECTIN2-TIGIT axis as a potential target for immunotherapy.

bioRxiv · Jul 15, 2022Cancer Biology

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

T. K. Olsen, C. Dyberg, B. Embaie, A. Alchahin, J. Milosevic, J. Otte, C. Tummler, I. H. Myrberg, E. M. Westerhout, J. Koster, R. Versteeg, P. Kogner, J. I. Johnsen, D. B. Sykes, N. Baryawno

This study identifies DHODH as a prognostic marker and therapeutic target in neuroblastoma, showing its inhibition improves survival in preclinical models and suggests combination therapy with temozolomide.

bioRxiv · Sep 25, 2021Cancer Biology

An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite

T. van Groningen, C. U. Niklasson, A. Chan, N. Akogul, E. M. Westerhout, K. von Stedingk, M. Hamdi, L. J. Valentijn, S. Mohlin, P. Stroeken, N. E. Hasselt, F. Haneveld, A. Lakeman, D. A. Zwijnenburg, P. van Sluis, , J. van Nes

The paper identifies an immature neuroblastoma subset that synthesizes retinoic acid and is resistant to it, potentially contributing to therapy-resistant relapses.

bioRxiv · May 18, 2021 · PreprintCancer Biology

Tumors widely express hundreds of embryonic germline genes

J. W. Bruggeman, N. Irie, P. Lodder, A. M. M. van Pelt, J. Koster, G. Hamer

The paper identifies 672 germ cell cancer genes, expanding the known pool by 51%, and suggests they may offer better cancer treatment targets with fewer side effects.

bioRxiv · Sep 8, 2020Cancer Biology

SOX11 is a lineage-dependency factor and master epigenetic regulator in neuroblastoma

B. Decaesteker, A. Louwagie, S. Loontiens, F. De Vloed, J. Roels, S. Vanhauwaert, S. De Brouwer, E. Sanders, G. Denecker, E. D'haene, S. Van Haver, W. Van Loocke, J. Van Dorpe, D. Creytens, N. Van Roy, , F. Speleman

This study identifies SOX11 as a critical transcription factor and epigenetic regulator in adrenergic neuroblastoma, showing its role in chromatin accessibility and cell identity.

bioRxiv · Aug 21, 2020 · PreprintCancer Biology

Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140

M. Ghiboub, J. Koster, P. D. Craggs, A. Y. F. Li Yim, A. Shillings, S. Hutchinson, R. P. Bingham, K. Gatfield, I. L. Hageman, G. Yao, H. P. O'Keefe, A. Coffin, A. Patel, L. A. Sloan, D. J. Mitchell, , W. J. de Jonge

This study identifies SP140 as a druggable epigenetic reader and therapeutic target for Crohn's disease by showing that its inhibition reduces inflammatory macrophage activation and cytokine expression.

bioRxiv · Aug 10, 2020Immunology

Social integration predicts survival in female white-faced capuchin monkeys

K. KAJOKAITE, A. Whalen, J. Koster, S. Perry

The paper finds that social integration in female white-faced capuchin monkeys is associated with increased survivorship, particularly through interactions with females and males.

bioRxiv · Aug 4, 2020Animal Behavior & Cognition

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells

E. Matas-Rico, E. Frijlink, I. van der Haar Avila, A. Menegakis, M. van Zon, A. J. Morris, J. Koster, F. Salgado-Polo, S. de Kivit, T. Lanca, A. Mazzocca, Z. Johnson, J. Haanen, T. N. Schumacher, A. Perrakis, , W. H. Moolenaar

This study shows that ATX secreted by melanoma cells repels CD8+ T cells, reducing their infiltration into tumors and impairing anti-tumor immunity.

bioRxiv · Feb 26, 2020Cancer Biology

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

T. F. Eleveld, L. Vernooij, L. Schild, B. Koopmans, L. K. Alles, M. E. Ebus, P. G. van Sluis, H. N. Caron, J. Koster, R. Versteeg, E. M. Dolman, J. J. Molenaar

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.

bioRxiv · Feb 12, 2020 · PreprintCancer Biology

The Life History of Human Foraging: Cross-Cultural and Individual Variation

J. Koster, R. McElreath, K. Hill, D. Yu, G. Shepard, N. van Vliet, M. Gurven, H. Kaplan, B. Trumble, R. Bliege Bird, D. Bird, B. Codding, L. Coad, L. Pacheco-Cobos, B. Winterhalder, , C. Ross

The paper analyzes hunting skill data from 1,800 individuals to infer age-related productivity patterns and variation in human foraging.

bioRxiv · Mar 12, 2019Animal Behavior & Cognition

A Tumor Suppressor-Regulated Cell Cycle Derived Gene Signature Is Prognostic Of Recurrence Risk In Prostate Cancer

C. Georgescu, J. M. Corbin, S. Thivibilliers, Z. D. Webb, Y. D. Zhao, J. Koster, K.-M. Fung, A. S. Asch, J. D. Wren, M. J. Ruiz Echevarria

The paper develops a gene signature based on Tmeff2-regulated cell cycle genes that predicts recurrence risk in prostate cancer and outperforms existing prognostic markers.

bioRxiv · Aug 21, 2018Cancer Biology